3D Systems entered 2026 with its clearest operating improvement in years. Dental, medtech and aerospace demand strengthened, gross margin improved and adjusted EBITDA turned positive. Then, less than a month later, the company raised $50 million through a new equity offering.
The contrast captures the investment case. The product and market thesis is improving. The balance-sheet and cash-generation thesis is not yet solved.
Addithive verdict
Thesis status: Operationally strengthening, financially still fragile.
3D Systems is showing real commercial momentum in digital dentistry and medtech. The next proof point is whether that growth can fund the business without repeated dilution.
What changed?
- Q1 2026 revenue reached $95.5 million, up 1% year over year and 11% excluding divestitures.
- Healthcare Solutions revenue increased approximately 21% to $50.1 million.
- Dental, medtech and aerospace & defense each grew more than 20%.
- Gross margin improved to 35.9%, from 34.6%.
- Adjusted EBITDA improved to positive $2.1 million, from a large loss a year earlier.
- ROE Dental expanded its fleet of NextDent 300 systems across multiple sites.
- 3D Systems priced a $50 million upsized public offering at $3.05 per share.
Why dental matters more than a normal product cycle
Digital dentistry is one of the few additive-manufacturing markets with repeatable production volumes, recurring materials demand and a clear replacement path for conventional workflows.
3D Systems’ NextDent 300 jetted-denture solution targets monolithic, multi-material dentures. The significance is not only print speed. It is the possibility of combining automation, consistency and labor reduction in a market still dependent on skilled manual processes.
ROE Dental’s decision to add systems across multiple locations is a stronger commercial signal than a first installation. It suggests that the platform has moved beyond evaluation and is being deployed to expand real manufacturing capacity.
Healthcare is becoming the center of the company
Healthcare revenue now rivals the Industrial segment. That shift matters because dental and medtech applications can offer better utilization, recurring materials sales and more resilient demand than discretionary capital-equipment markets.
3D Systems also benefits from decades of regulatory, workflow and application knowledge. In healthcare, the moat is not simply the printer. It is the validated combination of hardware, materials, software and process expertise.
The Q1 recovery was real
Excluding divested software businesses, revenue grew 11%. Adjusted EBITDA improved by more than $25 million year over year and turned positive. Net loss also narrowed sharply.
This was not only a cost-cutting quarter. Growth in healthcare and aerospace & defense contributed to better mix and higher gross margin.
However, one positive quarter does not establish a durable earnings model. System demand remains cyclical, and product launches require working capital, inventory and commercial investment before revenue fully scales.
Why the equity raise changes the interpretation
In June, 3D Systems sold 16.4 million shares at $3.05 per share for approximately $50 million in gross proceeds. The underwriters also received an option for additional shares.
The capital strengthens liquidity and gives management more room to fund launches and operations. But it also dilutes existing shareholders and shows that the operating turnaround has not yet generated enough internal cash to remove financing risk.
The important question is therefore not whether the raise was necessary. It is whether this capital funds a self-sustaining growth cycle—or simply extends the runway until the next raise.
The strongest version of the thesis
The bull case is that 3D Systems has exited weaker software assets, reduced costs and concentrated resources on markets where it has genuine application depth. Dental, medtech and aerospace then drive higher-margin growth, while the installed base produces recurring materials and service revenue.
Under that scenario, the June offering becomes bridge capital used before a sustained profitability inflection.
The weaker version of the thesis
The bear case is that healthcare growth remains too narrow to offset cyclicality elsewhere, new-product adoption takes longer than expected and positive adjusted EBITDA fails to convert into positive free cash flow.
Under that scenario, dilution becomes a recurring feature rather than a one-time bridge.
What would prove the thesis?
- Dental and medtech sustain double-digit growth.
- ROE and other labs place follow-on NextDent 300 orders.
- Healthcare remains at least half of revenue with improving margins.
- Adjusted EBITDA stays positive over multiple quarters.
- Operating cash flow and free cash flow improve materially.
- Recurring materials and service revenue rise with installed-base utilization.
- The company avoids another major equity raise.
- Aerospace and defense product launches convert into repeat production orders.
What would break the thesis?
- Dental growth slows after the initial launch cycle.
- New systems are installed but underutilized.
- Gross margin fails to expand despite better mix.
- Positive adjusted EBITDA does not convert into cash.
- Industrial weakness overwhelms healthcare growth.
- Further financing creates substantial additional dilution.
- Product launches or regulatory approvals are delayed.
Research conclusion
3D Systems’ Q1 improvement was credible. Core revenue grew, healthcare became more important, dental adoption accelerated and adjusted EBITDA turned positive.
The $50 million equity raise does not invalidate that progress. It does, however, show that the turnaround is not yet self-funding.
For investors, the decisive milestone is now cash conversion. Product momentum has returned. Financial independence has not.
Research use only. This article is not investment advice.
Read the full 3D Systems investor profile →